focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company - Tate & Lyle Contract

11 Dec 2012 07:00

RNS Number : 1970T
Frontier IP Group plc
11 December 2012
 



 

 

 

 

 

AIM: FIPP

 

 

FRONTIER IP GROUP PLC

("Frontier IP" or "the Group")

 

Portfolio company signs licence agreement with Tate & Lyle

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that its portfolio company, Nandi Proteins Limited ("Nandi"), has concluded a licence agreement for the use of its innovative protein technology with Tate & Lyle PLC ("Tate & Lyle"), the global provider of ingredients and solutions to the food and beverage sectors. As reported on 6 November 2012, the conclusion of these licence terms will result in the payment of advisory fees to Frontier IP and is expected to result in an uplift in the valuation of Frontier IP's holding in Nandi, which is a spin-out company from Heriot Watt University in Edinburgh.

 

The agreement grants Tate & Lyle an exclusive worldwide licence to use aspects of Nandi's protein technology for food and beverage applications. Tate & Lyle will be responsible for developing the technology further for new food and beverage ingredients primarily relating to its texturant portfolio.

 

Nandi's protein technology has wide-ranging application in the food sector and potentially beyond. The technology improves the functional properties of common proteins and in food and beverage applications can boost the textural attributes, or 'mouthfeel', of certain food products.

 

Neil Crabb, Chief Executive, commented,

 

"I am delighted to report that our portfolio company, Nandi, has concluded its licence agreement with Tate & Lyle. Tate & Lyle look for innovations that will lead to exciting new food and beverage ingredients and Nandi's technology offers this. The agreement also reflects Nandi's strategy of developing partnerships with major industry players, which continues."

 

 

 

Enquiries

Company website: www.frontierip.co.uk

 

Frontier IP Group Plc

T: 0131 220 9491

Neil Crabb, Chief Executive

Seymour Pierce Ltd (Nominated Adviser and Joint Broker)

T: 020 7107 8000

Guy Peters / Julian Erleigh - Corporate Finance

David Banks / Paul Jewell - Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

Biddicks

T: 020 3178 6378

Katie Tzouliadis

 

 

 

 

 

 

Notes to Editor:

 

Frontier IP Group Plc ("Frontier IP")specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes.

 

Nandi Proteins Limited ("Nandi") is a sales, marketing, IP and licensing company spun out of Heriot Watt University, Edinburgh in 2001. The company was established to exploit patented process technology and know how to improve the functional properties of common proteins such as whey, egg and soy. The company's objective is to become a market leader in the field of denatured protein technology. Denatured egg and dairy proteins are currently being produced on a factory scale and have been successfully used in applications by major companies in the food industry.

Tate & Lyle PLC ("Tate & Lyle") is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world. Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by Innovation and Commercial Development. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving the Bulk Ingredients business for sustained cash generation to fuel this growth.

Speciality Food Ingredients include starch-based speciality ingredients (corn-based speciality starches, sweeteners and fibres), no calorie sweeteners (including SPLENDA® Sucralose) and Food Systems which provides blended ingredient solutions. Bulk Ingredients include corn-based bulk sweeteners, industrial starches and fermentation products (primarily acidulants). The co-products from both divisions are primarily sold as animal feed.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMMMZRGNGZZM
Date   Source Headline
15th Nov 201812:37 pmRNSGrant of Options
15th Nov 201810:05 amRNSExscientia acquires Kinetic Discovery
15th Nov 20189:30 amRNSPlacing to raise £2.49 million
15th Nov 20189:25 amRNSFinal Results
30th Oct 20187:00 amRNSSecond Portuguese spin out: Des Solutio
19th Oct 20187:00 amRNSMolendotech signs collaboration agreement with G's
5th Oct 20187:00 amRNSDIT hails Frontier IP's Portuguese success
27th Sep 20187:00 amRNSChange of Adviser
26th Sep 20185:12 pmRNSDirector Declaration
24th Sep 20182:30 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSAmprologix to develop new antibiotics with Ingenza
18th Sep 20181:56 pmRNSAlusid raises £1.34m to scale up manufacturing
17th Sep 20187:00 amRNSAB Sugar Head of Innovation joins Frontier IP
30th Aug 201812:39 pmRNSHolding(s) in Company
15th Aug 20187:00 amRNSTVG awarded £50,000 anti-bacterial vaccine grant
7th Aug 20187:00 amRNSPortfolio news - first Portuguese spin out
6th Aug 20187:00 amRNSFieldwork Robotics agreement with Hall Hunter
2nd Aug 20187:00 amRNSFrontier IP partners with UK DIT in Portugal
16th Jul 20187:00 amRNSTarsis Collaboration with Crop-Protection Company
11th Jul 20187:00 amRNSInnovate UK grant for Pulsiv Solar
19th Jun 20187:00 amRNSCambridge Material Testing Solutions
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics
27th Mar 20187:00 amRNSHALF-YEAR RESULTS, 6 MONTHS TO 31 DECEMBER 2017
26th Mar 20187:00 amRNSTeam Expansion and London Office
19th Feb 20187:00 amRNSPortfolio News - Molendotech Secures First Funding
29th Jan 20187:00 amRNSCapital Markets Day
29th Jan 20187:00 amRNSPortfolio News - Molendotech Collaboration
18th Dec 20177:00 amRNSCapital Markets Day
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration
30th Mar 20177:00 amRNSHalf-Year Results for the 6 Months to 31 Dec 2016

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.